Leukemia, also known as blood cancer, prevents a person from fighting the infection. It is characterized by the formation of tumors in hematopoietic tissues, including bone marrow. The different types of leukemia include acute lymphoblastic leukemia, acute myeloid leukemia, and chronic lymphocytic leukemia. Fatigue, weight loss, frequent infections and easy bleeding or bruising are some of the symptoms of this disease. Treatment for early leukemia includes surveillance and severe leukemia is treated with chemotherapy followed by radiotherapy and stem cell transplantation.
Asia Pacific Leukemia Therapeutics Market size was around USD 1.47 billion in 2018. It is expected to grow at a CAGR of 11.2% to reach USD 2.51 billion by 2023.
Drivers and Restraints:
Increasing geriatric population base, according to WHO leukemia is the most common blood cancer, innovative therapies for leukemia treatment, rising investment in healthcare sectors. Restraints of the market are high cost required for new development and government restrictions for approval.
The Asia Pacific Leukemia Therapeutics Market has geographically segmented into China, India, Japan, South Korea, and Australia. Asia-Pacific market is growing at very high rate, due to rising consumer market, favorable government support for enhanced healthcare infrastructure, and rising awareness for healthcare among the population in developing nations of the region.
Major companies in the market are F. Hoffmann-La Roche Ltd, GlaxoSmithKline Pharmaceuticals Limited, Novartis International AG, Bristol-Myers Squib, Eisai Co. Ltd, Biogen Idec, ERYtech Pharma, Celgene Corporation, Genmab A/S, Cephalon Inc., Clavis Pharma, and Pfizer Inc.
Scope of the report:
The report offers a comprehensive analysis of the industry by providing the estimations of market potential and forecasts with utmost granularity. Along this, the factors influential in effecting the market dynamics and trends are discussed in detail at the product level. Further, the performance of the market at the regional and country-level is assessed and the prospects with high growth potential are identified and debated.
The key players in the industry are profiled providing insights on their financial performance, market position and growth strategies. Comparative analysis on prime strategically activities of the market players delineating the key developments like mergers & acquisitions, collaborations and an evaluation of the competitive environment within the industry are provided. The report also offers a broad outlook of the market along with recommendations from industry experts on the opportunities for investment activity.
What else? Apart from the syndicated report, our in-house team has an expertise and experience in designing custom reports to meet your specific research needs and assist you in making well-informed decisions.